TD Asset Management
TGTX icon

TD Asset Management’s TG Therapeutics TGTX Stock Holding History

TD Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,087
Closed -$375K – 1449
2023
Q2 		$375K Buy
+15,087
New +$390K ﹤0.01% 1306
2021
Q3 		– Sell
-25,591
Closed -$895K – 1553
2021
Q2 		$895K Sell
25,591
-1,916
-7% -$75.2K ﹤0.01% 1285
2021
Q1 		$1.33M Buy
27,507
+5,257
+24% +$253K ﹤0.01% 1209
2020
Q4 		$1.16M Buy
+22,250
New +$752K ﹤0.01% 1151

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

TD Asset Management's TGTX Position: Q3 2023 in Review

TD Asset Management sold out of TG Therapeutics (TGTX) in Q3 2023, closing a stake of 15,087 shares — an estimated $375K sold.

TD Asset Management first reported a position in TGTX in Q4 2020 and held it in 4 quarters. The position peaked at $1.33M in Q1 2021. 236 funds tracked by Wall St. Rank hold TGTX as of Q3 2023.

  • TD Asset Management reported no remaining TG Therapeutics position as of Q3 2023 after selling out during the quarter.
  • TD Asset Management sold 15,087 TG Therapeutics shares in Q3 2023, an estimated $375K.
  • TD Asset Management first reported a position in TG Therapeutics in Q4 2020 and held it in 4 quarters.
  • TD Asset Management's TG Therapeutics position peaked at $1.33M in Q1 2021.
  • 236 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2023.

Based on TD Asset Management's 13F filing for Q3 2023, filed 27 Oct 2023.